Aescap invests in high-growth companies that develop and market highly innovative medicines.
Our net performance over 2019 is 8%, while our cumulative net performance since inception in March 2016 is 86%.
The next information meeting will be held March 13 in Amsterdam for those who are interested. In this meeting our investment philosophy, as well as methodology are discussed in an interactive setting.
Our investment decisions are based on thorough research and fundamental analyses. In the biotech sector such an analysis especially encompasses product portfolio patent protection, product development risks, market entry barriers, competition and the expected market development.
But equally important are the serious efforts we undertake to understand the strengths and weaknesses of a company’s management, team dynamics, and their view on the future of the company and the markets they serve.